SCHEMBL1269540

SCHEMBL1269540

CCOC(=O)c1nc(N)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
CYP1A2 P05177 4/20 0.46
TARBP2 Q15633 2/20 0.46
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAOA P21397 1/20 0.45
MEN1 O00255 6/20 0.44
MAPT P10636 6/20 0.44
KMT2A Q03164 6/20 0.44
ALOX15 P16050 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
USP2 O75604 1/20 0.43
HSD17B10 Q99714 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2527315 0.84 TARBP2 (0.46) ALDH1A1CYP1A2TARBP2LMNAMAPT
SCHEMBL28033848 0.83 ALDH1A1 (0.49) ALDH1A1CYP1A2TARBP2LMNACYP3A4
SCHEMBL4908919 0.83 TARBP2 (0.48) ALDH1A1CYP1A2TARBP2MEN1MAPT
SCHEMBL19715739 0.83 TARBP2 (0.48) ALDH1A1CYP1A2TARBP2MAPTKMT2A
SCHEMBL18132220 0.82 CYP1A2 (0.59) ALDH1A1CYP1A2TARBP2MEN1MAPT
SCHEMBL1268827 0.81 NPSR1 (0.47) ALDH1A1CYP1A2CYP3A4MEN1KMT2A
SCHEMBL18132180 0.81 TARBP2 (0.44) ALDH1A1CYP1A2TARBP2LMNACYP3A4
SCHEMBL4903491 0.81 TARBP2 (0.46) ALDH1A1CYP1A2TARBP2MAPTKMT2A
SCHEMBL30200423 0.81 TARBP2 (0.46) ALDH1A1CYP1A2TARBP2LMNAMAPT
SCHEMBL24550618 0.79 PDE10A (0.46) ALDH1A1CYP1A2TARBP2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 CN disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885CYP1A2 570/4885TARBP2 996/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885CYP1A2 570/4885TARBP2 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.